Legrex (Ticagrelor)

• Legrex is a P2Y12 receptor antagonist used in the antiplatelet therapy pathway for cardiovascular disease.
• Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke.
• Myocardial infarction: prevents recurrent ischemic events after an acute heart attack.
• Post‑percutaneous coronary intervention: lowers the incidence of stent thrombosis and related complications.

• Ticagrelor reversibly binds to the platelet P2Y12 ADP receptor, blocking ADP-mediated activation of the G_i protein pathway. This inhibition prevents the conformational change of the GPIIb/IIIa receptor, thereby reducing fibrinogen binding and platelet aggregation, leading to an antithrombotic effect without requiring metabolic activation.

Legrex may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Dyspnea: shortness of breath, often transient.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Diarrhea: loose stools, usually self‑limiting.
• Increased uric acid: may raise serum levels.
• Dizziness: occasional light‑headedness.

Serious or Rare Side Effects

• Severe bleeding: life‑threatening hemorrhage, including intracranial bleeding.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Thrombocytopenia: marked reduction in platelet count.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.

Before initiating Legrex, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

• Assess bleeding risk: review history of hemorrhage or coagulopathy.
• Monitor liver function: check baseline enzymes and repeat as indicated.
• Adjust for renal impairment: consider dose modification in severe renal dysfunction.
• Avoid in active pathological bleeding: discontinue if uncontrolled bleeding occurs.
• Use caution in elderly patients: increased susceptibility to bleeding.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Legrex can interact with several drug classes, influencing its antiplatelet efficacy or bleeding risk.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor plasma concentrations.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
• Concurrent use of anticoagulants (e.g., warfarin, heparin): markedly raises bleeding risk.

Moderate Interactions (Monitor Closely)

• Aspirin or other NSAIDs: additive effect on bleeding.
• Other antiplatelet agents (e.g., clopidogrel): may enhance antithrombotic activity.
• Statins metabolized by CYP3A4 (e.g., simvastatin): may increase exposure; dose adjustment may be needed.